Bliss GVS Pharma: Anupam Rasayan group acquires control; 3 new directors appointed
Anupam Rasayan India Limited, through PAC, acquired 47.95% stake in Bliss GVS Pharma Limited on September 28, 2026, becoming the new promoter. Three new directors, Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat, were appointed. Managing Director Narsimha Shibroor Kamath resigned.
A change in promoter status and board composition signifies a substantial shift in the company's control and strategic direction, which is expected to have a high impact on its operations and future performance.
The acquisition of control by a new promoter group and the appointment of experienced directors suggest a positive outlook for the company's future strategic direction and governance.
Bliss GVS Pharma Limited announced a significant change in its control and promoter status following the completion of a share purchase agreement (SPA). On September 28, 2026, Anupam Rasayan India Limited, through its associate Mates Visa Consultancy Private Limited (PAC), acquired 5,09,84,595 equity shares, representing 47.95% of the company's equity. This acquisition, combined with shares from an open offer, brings the total holding of Anupam Rasayan India Limited and PAC to 47.95%, establishing them as the new promoters of Bliss GVS Pharma Limited.
In line with the change in control, the Board of Directors also approved the appointment of three new Non-Executive Non-Independent Directors, effective September 28, 2026. These include Mr. Hetul Krishnakant Mehta, an entrepreneur with over 30 years of experience in the pharmaceutical industry; Mr. Amar Dilip Shah, a business professional with extensive experience in sales, marketing, and strategic planning; and Mr. Pramod Badrinarayan Kasat, a seasoned Investment Banker with over three decades of experience in structured finance and investment banking.
Concurrently, Mr. Narsimha Shibroor Kamath resigned from his position as the Managing Director of the company, effective September 28, 2026. The Board noted and accepted his resignation, which is in connection with the completion of the SPA transactions and the consequent change in control. The company also approved a Postal Ballot Notice seeking member approval for the appointment of the three new directors.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.